Research programme: liver X receptor modulators - Karo Pharma/Pfizer

Drug Profile

Research programme: liver X receptor modulators - Karo Pharma/Pfizer

Alternative Names: WAY-252623; WAY-254011; WYE-672

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Karo Bio
  • Developer Pfizer
  • Class Indazoles; Quinolines
  • Mechanism of Action Liver X receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Atherosclerosis; Inflammation

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Atherosclerosis in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA (PO)
  • 17 Jul 2012 Due for review, but nothing appears to have changed so just did a quick check. No further publications on google, nothing in Pfizer website but still listed as late research/early preclin for inflammation on Karo website so left dev as is, and added active statement.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top